Literature DB >> 34996086

Antiphospholipid Antibodies and the Antiphospholipid Syndrome: From Coagulation to the Clinic.

Rita Selby1, Jameel Abdulrehman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34996086      PMCID： PMC8741326          DOI： 10.1093/jalm/jfab134

Source DB:  PubMed          Journal:  J Appl Lab Med        ISSN： 2475-7241


× No keyword cloud information.
  27 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

Review 2.  Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I--Anticardiolipin and anti-β2-glycoprotein I antibodies.

Authors:  Emmanuel J Favaloro; Loretta Wheatland; Sue Jovanovich; Peter Roberts-Thomson; Richard C W Wong
Journal:  Semin Thromb Hemost       Date:  2012-05-08       Impact factor: 4.180

Review 3.  The pathogenesis of the antiphospholipid syndrome.

Authors:  Bill Giannakopoulos; Steven A Krilis
Journal:  N Engl J Med       Date:  2013-03-14       Impact factor: 91.245

4.  Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  Stéphane Zuily; Hannah Cohen; David Isenberg; Scott C Woller; Mark Crowther; Virginie Dufrost; Denis Wahl; Caroline J Doré; Adam Cuker; Marc Carrier; Vittorio Pengo; Katrien M J Devreese
Journal:  J Thromb Haemost       Date:  2020-09       Impact factor: 5.824

5.  Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: A multicenter multiplatform study.

Authors:  Dongmei Yin; Walid Chayoua; Hilde Kelchtermans; Philip G de Groot; Gary W Moore; Jean-Christophe Gris; Stéphane Zuily; Jacek Musial; Bas de Laat; Katrien M J Devreese
Journal:  J Thromb Haemost       Date:  2020-02       Impact factor: 5.824

6.  Addendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulants.

Authors:  Deepa R J Arachchillage; Keith Gomez; Raza Alikhan; Julia A M Anderson; Will Lester; Mike Laffan
Journal:  Br J Haematol       Date:  2020-01-13       Impact factor: 6.998

7.  Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort.

Authors:  Vicky Tagalakis; Valérie Patenaude; Susan R Kahn; Samy Suissa
Journal:  Am J Med       Date:  2013-07-03       Impact factor: 4.965

8.  EULAR recommendations for the management of antiphospholipid syndrome in adults.

Authors:  Angela Tincani; Michael M Ward; Maria G Tektonidou; Laura Andreoli; Marteen Limper; Zahir Amoura; Ricard Cervera; Nathalie Costedoat-Chalumeau; Maria Jose Cuadrado; Thomas Dörner; Raquel Ferrer-Oliveras; Karen Hambly; Munther A Khamashta; Judith King; Francesca Marchiori; Pier Luigi Meroni; Marta Mosca; Vittorio Pengo; Luigi Raio; Guillermo Ruiz-Irastorza; Yehuda Shoenfeld; Ljudmila Stojanovich; Elisabet Svenungsson; Denis Wahl
Journal:  Ann Rheum Dis       Date:  2019-05-15       Impact factor: 19.103

Review 9.  14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

Authors:  Maria Laura Bertolaccini; Olga Amengual; Laura Andreoli; Tatsuya Atsumi; Cecilia B Chighizola; Ricardo Forastiero; Philip de Groot; Gabriella Lakos; Marc Lambert; Pierluigi Meroni; Thomas L Ortel; Michelle Petri; Anisur Rahman; Robert Roubey; Savino Sciascia; Melissa Snyder; Anne E Tebo; Angela Tincani; Rohan Willis
Journal:  Autoimmun Rev       Date:  2014-05-10       Impact factor: 9.754

10.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Authors:  Vittorio Pengo; Gentian Denas; Giacomo Zoppellaro; Seena Padayattil Jose; Ariela Hoxha; Amelia Ruffatti; Laura Andreoli; Angela Tincani; Caterina Cenci; Domenico Prisco; Tiziana Fierro; Paolo Gresele; Arturo Cafolla; Valeria De Micheli; Angelo Ghirarduzzi; Alberto Tosetto; Anna Falanga; Ida Martinelli; Sophie Testa; Doris Barcellona; Maria Gerosa; Alessandra Banzato
Journal:  Blood       Date:  2018-07-12       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.